A system that combines CRISPR gene editing with a lipid nanoparticle delivery system could halt or even reverse the progression of Duchenne muscular dystrophy, according to work led by Penn Medicine researchers.
The approach brings together two delivery systems that are already in use, with the researchers suggesting the combination could change how the disease is treated.
"We believe that combining a pair of delivery systems already in use has great therapeutic potential and could lead to a significant change in how we treat this disease," said senior author Tejvir S. Khurana.
The findings were announced by the University of Pennsylvania on October 29, 2026, as part of Penn Today's health and medicine coverage.
Duchenne muscular dystrophy is the condition targeted by the research, which pairs CRISPR gene editing with lipid nanoparticles — the delivery vehicles used to carry genetic material into cells.
The work was led by researchers at Penn Medicine, the university's medical school and health system.
The announcement did not include further details on the study's methods, results or timeline for clinical application.